NCT01435720Unknown1 期
Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients With Relapsed or Refractory B Cell Malignancies
Senesco Technologies, Inc.12 个研究点 分布在 2 个国家目标入组 15 人开始时间: 2011年9月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 15
- 试验地点
- 12
- 主要终点
- Safety and tolerability
研究概览
简要总结
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.
详细描述
The main purpose is to test the safety and tolerability of SNS01-T. The first group of patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma will be given a relatively low dose. If tolerated, a second group will receive a higher dose. If tolerated by the second group, a third and then a fourth group will receive higher doses. Treatment-related adverse events (side effects), changes in vital signs, physical examination, and laboratory values will be monitored. Patients will receive twice weekly infusions for 6 weeks and then will be followed monthly for 6 months. A secondary purpose is to explore whether SNS01-T is an effective treatment for multiple myeloma, B cell lymphoma and plasma cell leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •B cell lymphoma patients must have had their diagnosis confirmed histologically. Plasma cell leukemia (PCL) patients must have peripheral clonal plasma cells >20% of peripheral WBC and >2 x 109/L. Multiple myeloma and PCL patients must have been diagnosed by having met all three of the following IMWG criteria:
- •Clonal bone marrow plasma cells >10%
- •Presence of serum and/or urinary M-protein or, if absent, kappa or lambda serum FLC must be > 10 mg/dl accompanied by an abnormal kappa to lambda ratio (<0.26 or >1.65)
- •Evidence of end-organ damage that can be attributed to the underlying plasma cell proliferative disorder, specifically, one or more of the following:
- •Hypercalcemia: serum calcium >11.5 mg/100 mL
- •Renal insufficiency: serum creatinine >2mg/dL
- •Anemia: normochromic, normocytic with a hemoglobin value >2 g/100 mL below the lower limit of normal or a hemoglobin value <10 g/100 mL
- •Bone lesions: lytic lesions, severe osteopenia, or pathologic fractures
- •B cell lymphoma patients must have measurable disease defined as at least one lesion that can be accurately measured for response in at least two perpendicular dimensions. Multiple myeloma patients must have measurable disease defined by the following:
- •Serum M-protein ≥0.5g/dL or urine M-protein ≥ 200 mg/24 hours by protein electrophoresis
- •If neither serum nor urine M-protein meet the criteria above, then kappa or lambda serum FLC must be ≥10 mg/dL accompanied by an abnormal kappa to lambda ratio (<0.26 or >1.65) (Serum FLC should only be used for patients without measurable serum or urine M-protein spike.)
- •If neither of the above criteria are met, the presence of plasmacytomata measurable radiographically (CT, PET or MRI) or by direct measurement.
- •Have relapsed or refractory disease after two or more prior treatment lines, each of which may have consisted of either single or multiple regimens. The investigators will ensure that patients have had the benefit of standard treatments before considering the SNS01-T clinical trial.
- •Be at least 2 weeks beyond the last therapy and have recovered from acute toxicities of prior therapies
- •Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Have life expectancy of at least 3 months
- •Be ≥18 years of age and willing to provide written informed consent
- •For women and men of childbearing potential, have used effective contraceptive methods for at least 4 weeks prior to dosing and agree to continue using such methods during the study, and for at least 4 weeks after completing the study
- •For women of childbearing potential, have a negative serum pregnancy test within 24 hours before the initiation of SNS01-T therapy
- •Have an absolute neutrophil count >1,000/mm3
- •Have a platelet count >75,000/mm3
- •Have total bilirubin <2.0 mg/dL
- •Have aspartate aminotransferase and alanine aminotransferase <3 times the upper limit of normal
- •Have serum creatinine ≤3 times the upper limit of normal
- •Have hemoglobin ≥8.0 g/dL
排除标准
- •Have presence of nonsecretory myeloma
- •Have an indolent lymphoma such as follicular lymphoma unless the disease is rapidly progressing
- •Requires renal dialysis
- •Have New York Heart Association Class III-IV heart failure classification
- •Have CNS or leptomeningeal disease
- •Have an active infection or serious comorbid medical condition
- •Be receiving other concurrent anticancer agents or therapies
- •Be receiving other concurrent investigational therapies or have received investigational therapies within 4 weeks of screening or 5 half-lives, if known, whichever is shorter
- •Be eligible to receive any other standard therapy available that is known to extend life expectancy
- •Be currently receiving steroids unless equivalent to 20 mg of prednisone or less
- •Be receiving or have received heparin therapeutically within two days before and after treatment with SNS01-T
- •Be pregnant or nursing
结局指标
主要结局
Safety and tolerability
时间窗: Week 6
Safety and Tolerability assessed by frequency, severity, and duration of treatment-related adverse events, changes in vitals signs, physical exams and lab values
次要结局
- Profile of pharmacokinetics(0.5 hours pre-dose and 0.5, 2, 6 and 24 hours post-dose)
- Explore tumor response(Weeks 3 and 6, and monthly during a 24-week follow-up period)
研究者
研究点 (12)
Loading locations...
相似试验
已完成
不适用
Phase II study of S-1 for relapsed or refractory thymoma or thymic carcinomaThymoma/Thymic carcinomaJPRN-UMIN000008174orth Japan Lung Cancer Group40
已完成
2 期
Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in AdultsLateral Canthal LinesCrow's FeetFacial WrinklesNCT01124565Revance Therapeutics, Inc.40
已完成
1 期
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid MalignanciesB-lymphoid MalignanciesMultiple MyelomaChronic Lymphocytic LeukemiaMantle Cell LymphomaNCT00446342Sunesis Pharmaceuticals21
已完成
1 期
Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)NCT02227459Bristol-Myers Squibb25
终止
1 期
AZD7325 Japan Multiple Ascending Dose (MAD) StudyHealthyNCT00945425AstraZeneca48